FinlandFinland

Orion and Abbott Expand Agreement

08.05.2004

Espoo - Finish Orion Corporation, Espoo, and Abbott Laboratories Inc. (USA) have in April expanded their licensing agreement for the injectable formulation of Orion's proprietary drug Levosi-mendan (marketed as Simdax®) for the treatment of acutely decompensated heart failure. Levosimendan, a calcium sensi-tizer, is available in an intravenous formulation and approved in some 30 countries. It is currently in phase III clinical studies in the US and Europe and has been granted fast-track status by the FDA. Abbott will make an upfront payment to Orion of Euro10 million. Orion will receive milestone payments upon meeting specified development and commercial milestones and will receive a percentage of Abbott's net sales of Levosimendan. Further financial terms were not disclosed.
As of April 1 the Finnish corporate name of the company is Orion Oyj. The corporate name in English remains as Orion Corporation.

FinlandFinland

08.03.2012

The vaccine research centre of the University of Tampere in Finland has out­licenced a candidate combined prophylactic vaccine against norovirus and rota­virus infections. The Japanese vaccine venture UMN Pharma Inc. acquired the...

FinlandFinland

07.03.2012

Finnish protein manufacturer Vectron Biosolutions AS has completed a study comparing different expression technologies. According to Vectron, their proprietary E. coli expression technology gave higher yields for seven out of ten...

FinlandFinland

02.03.2012

Lappeenranta – Finnish paper industry major UPM plans to invest in an industry-scale biorefinery producing biofuels from crude tall oil, a by-product of the wood pulp manufacturing process. UPM’s total investment will amount to...

FinlandFinland

18.12.2011

Helsinki/Göttingen – Finnish laboratory supplier Biohit Oyj has sold its liquid handling business for €68m to German process and labtech provider Sartorius AG. Osmo Suovaniemi, founder and Chairman of the Board at Biohit,...

FinlandFinland

17.12.2011

Porvoo/Chalfont St. Giles – GE Healthcare and Neste Jacobs have formed a strategic alliance to drive worldwide self-sufficiency in blood plasma fractionation. Finnish-based Neste Jacobs Oy, a global expert in plant engineering...

FinlandFinland

31.10.2011

Bresso/Turku – The wedding's off between Newron and Biotie. The bride has run away. Shares in Italy's Newron Pharmaceuticals plunged after its proposed merger with Biotie Therapies Corp was called off by the Finnish firm....

FinlandFinland

28.09.2011

Turku/ Bresso – It is both good and bad news for the Italian biotechnology sector: Finnish Biotie Therapies ASA has signed an agreement to acquire Newron Pharmaceuticals S.p.A. for €45 million. On the down side, Italy loses one...

FinlandFinland

04.04.2011

Hafnarfjodur – Actavis Group CEO Claudio Albrecht announced at the beginning of February that the company may go public within the next 2-3 years, although it isn’t clear whether the generics manufacturer would conduct an IPO,...

Displaying results 1 to 10 out of 96

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-finland/article/orion-and-abbott-expand-agreement.html

Product of the week

Products

Events

All Events

Current issue

All issues